NOX Receives $3.26M Federal Govt R&D Rebate
Filed with ASX · · 2 pages · English
Earlier from Noxopharm
- DARRT-1 study advancing on basis of positive clinical data
- NOX announces Positive Data from CEP-1 Study of Veyonda
- NOX to Present Clinical Data at COSA Annual Meeting
- Appendix 4C - quarterly
- Change of Registry Address: Automic P/L - Sydney Office
Later from Noxopharm
- Principal Investigator Discusses LuPIN-1 Study
- Veyonda and Radiotherapy Delivers Clinical Benefits
- FNN interview with Nox Chief Medical Officer on Interim Data
- Noxopharm to expedite Veyonda Clinical Program
- KZA: Kazia sells stake in Noxopharm
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm